See other companies on Welcome to the Jungle

Depixus

Genetic analysis technology

Depixus logo
21-100 employees
  • Healthcare
  • B2B
  • Biology
  • Science
  • MedTech
Parc-de-Montsouris, Paris, France

Jump to section

Company mission

Depixus' goal is to commercialise a highly innovative technology platform for the fast, accurate, and inexpensive extraction of genetic and epigenetic information from single molecules of DNA and RNA.

36% employee growth in 12 months

Our take

As the cost of sequencing the human genome has drops to less than €900 today, in part thanks to advances in cloud computing, innovations in the bioinformatics space are prospering.

This has resulted in company's such as Depixus looking to expand the epigenetic field with new sequencing technology. Depixus (formerly PicoSeq) is undertaking development of a disruptive new technology for the swift, precise, and economical extraction of sequence and epigenetic information from long individual molecules of DNA and RNA.

Depixus's technology looks set to open new horizons in applications such as biomarker discovery for liquid biopsy cancer detection, virology, and the development of drugs targeting RNA.

Steph headshot

Steph

Company Specialist at Welcome to the Jungle

Funding (last 2 of 4 rounds)

Dec 2021

$35.4m

SERIES A

Nov 2018

$3.1m

GRANT

Total funding: $41.1m

Leadership

Gordon Hamilton

(CEO)

Gordon has a FirstClass Master’s degree in Physiological Sciences from the University of Oxford, a medical degree from Imperial College School of Medicine, and an MBA from INSEAD. Gordon has experience of translational research and bioscience commercialization after working as Medical Director for ChemoCentryx. Gordon previously founded and built-up The Electives Network Ltd, an international medical education company. Co-founded Depiux in 2012.

Chas Andre

(CTO)

Chas graduated from The University of Chicago with a bachelor’s degree in biology, and earned a Ph.D. in Genetics from Stanford University. Chas has over 17 years of experience working with companies such as Applied Biosystems, MJ Research; BioRad, and Thermo Fisher Scientific.